No difference in skin cancer incidence with or without cyclosporine--a 5-year perspective.
In the short perspective of 5 years, there was no difference in the incidence of malignant and premalignant skin lesions among patients with Aza- vs CyA-based immunosuppressive protocols, or when these drugs were combined. However, the risk of acquiring skin cancer increases with the length of immunosuppressive therapy. Another 5 to 10 years of experience with CyA will be needed to decide on any change in the established pattern of posttransplant skin complications.
Blohmé
I
I
Transplant Unit, Sahlgrenska Hospital, Göteborg, Sweden.
Larkö
O
O
D001379:Azathioprine / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000453:epidemiology / Q000209:etiology; D002280:Basal Cell Carcinoma / Q000453:epidemiology / Q000209:etiology; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000209:etiology; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007636:Keratoacanthoma / Q000453:epidemiology / Q000209:etiology; D016030:Kidney Transplantation; D011239:Prednisolone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000453:epidemiology* / Q000209:etiology
D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine